RENAL CELL CARCINOMA (RCC) IN YOUNG ADULTS: A CASE REPORT AND LITERATURE REVIEW Pediatric renal cell carcinoma (RCC) is a rare disease entity and found to show significant differences from adult RCC in terms of epidemiological and histological subtypes. Treatment strategies for paediatric RCC were mainly adopted from adult RCC as there’s no internationally recognized standard treatment guideline to date. Data on clinical outcomes are scarce. We hereby report a case of a 14-year-old female diagnosed with advanced clear cell RCC treated with pazopanib with overall survival of 10 months. There are several case reports and case series supporting the use of anti-VEGF in adolescent RCC though not in clear cell RCC. None has incorporated immune checkpoint inhibitors in adolescent RCC. Safety and efficacy in dosing strategies of anti-VEGF in adolescents is another challenge. As cancer care advances, large scale genetic data analysis leads to the emergence of precision and personalized medicine, but its utilisation in pediatric RCC is yet to be addressed.